एर्टापेनेम के इंटरैक्शन

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (एर्टापेनेम लेबल, दवाओं के इंटरैक्शन)

Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (एर्टापेनेम लेबल, दवाओं के इंटरैक्शन)

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (एर्टापेनेम लेबल, चेतावनियां और सावधानियां)